Cost implications of the use of basal insulin glargine in people with early dysglycemia The ORIGIN trial.pdf.pdf

Journal of Diabetes and plications 28 (2014) 553–558
Contents lists available at ScienceDirect
Journal of Diabetes and plications
journal homepage:
Cost implications of the use of basal insulin glargine in people with
early dysglycemia: The ORIGIN trial☆,☆☆
A. Lamy a,b,c,d,⁎, W. Tong a,b, H. Jung a, A. Gafni d,f, K. Singh g,h, J. Tyrwhitt a, S. Yusuf a,d,e,
. Gerstein a,e on behalf of the ORIGIN Investigators
a Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
b CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, Canada
c Department of Surgery, McMaster University, Hamilton, Ontario, Canada
d Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
e Department of Medicine, McMaster University, Hamilton, Ontario, Canada
f Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada
g All India Institute of Medical Sciences, New Delhi
h Centre for Chronic Disease Control, New Delhi
article info abstract
Article history: Aims: The cost implications of the e Reduction with an Initial Glargine Intervention (ORIGIN) trial
Received 27 August 2013 were evaluated using a prespecified analysis plan.
Received in revised form 31 January 2014 Methods: Purchasing power parity-adjusted country-specific costs were applied to consumed healt